Topics

IONTAS Announces New Antibody Optimisation Agreement With Teva Pharmaceuticals

04:58 EDT 29 Jul 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
IONTAS Limited (IONTAS), a leader in antibody discovery and optimisation of human monoclonal antibody libraries, today announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimisation of human antibodies f...

Other Sources for this Article

Zyme Communications
Lorna Cuddon
Tel: +44(0)7811 996 942
lorna.cuddon@zymecommunications.com

NEXT ARTICLE

More From BioPortfolio on "IONTAS Announces New Antibody Optimisation Agreement With Teva Pharmaceuticals"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...